Skip to content
Summus Laser Pod

The science

Not a red light bed.Superior technology.

Full‑body red‑light beds have used LEDs for years. The Pod uses therapeutic‑grade laser diodes — and the physics show up where it matters: in tissue.

01Laser, not LED

Same wavelength on paper.Different light in tissue.

Full-body red-light systems have historically used LEDs. A laser diode and an LED can share a nominal wavelength and still behave very differently once their light meets skin.

Summus Laser Pod · Class IV laser

Reaches deeper tissue

Directional and concentrated

LED-only bed · illustrative

Mostly superficial

Scattered in all directions

Illustrative · not to scale

  • 011–5 nm vs 20–60 nm

    Spectral purity

    Spectral width at half maximum: ~1–5 nm for laser diodes, 20–60 nm or more for LEDs.

  • 02High radiance · narrow divergence

    Directional emission

    Laser output is directional, with far higher radiance — power per unit area per unit solid angle. LEDs emit in a Lambertian pattern, scattered in all directions, so less of their output meets the skin at a useful angle.

  • 03Holds intensity across the body

    Distance stability

    LED irradiance drops steeply with distance and off-axis angle. At full-body enclosure distances, a laser beam holds its intensity far more consistently across the body’s curves.

  • 04Consistent across contours

    Dose predictability

    Narrow bandwidth, directional output and distance stability add up to a delivered dose you can actually predict — and prediction is what keeps every region of the body inside the therapeutic window.

02Key technologies

Three systems, onefifteen‑minute session.

01Unmatched power

Thirty‑two Class IV laser lenses

Each delivering up to 40 watts. No other system matches this output at full‑body scale — this is what makes whole‑body photobiomodulation possible in a single 15‑minute session.

32×40WClass IV emitters

02Intelligent software control

Automatic dose optimization

The control system continuously monitors the patient. Clinicians set the protocol — the system executes it with precision, managing session timing, power output and safety monitoring throughout. Choose from a library of pre‑built treatment protocols — simple enough for any trained staff member to operate.

1tapto start a protocol

03Safety systems

Engineered safety at every level

Automated session controls, real‑time thermal monitoring and multiple hardware interlocks halt operation if any parameter leaves the therapeutic range. Laser‑grade protective eyewear is provided and required.

cGMP‑built · FDA‑registered

03Technology in action

Where light becomescellular energy.

Class IV light stimulates cytochrome c oxidase in the mitochondria, increasing ATP — the fuel cells use to repair, recover and perform.

  1. Photon
    01Photon

    Photons enter tissue

    Red (~600–700 nm) and near-infrared (~800–1,000 nm) photons cross the skin. Most are absorbed in superficial tissue; a declining fraction travels deeper. Directional, narrow-band, high-radiance sources put a larger and more predictable share of that light where it is biologically useful.

    λ 600–1,000 nm · the optical window

  2. CCO
    02CCO

    Cytochrome c oxidase absorbs

    The principal photoacceptor is cytochrome c oxidase — complex IV of the mitochondrial respiratory chain, with absorption bands across the red and near-infrared. One widely cited proposed mechanism: light displaces inhibitory nitric oxide from the enzyme, freeing it to accelerate electron transport.

    Complex IV · respiratory chain

  3. ATP
    03ATP

    ATP synthesis rises

    Faster electron transport raises mitochondrial membrane potential and ATP output — more fuel for cellular repair and immune activity. A brief, modest rise in reactive oxygen species, together with the released nitric oxide, acts as a signal in its own right.

    ΔΨm rises · ATP rises · ROS / NO signaling

  4. Response
    04Response

    Cells respond — locally and systemically

    Those signals switch on transcription factors and downstream pathways tied to circulation, inflammatory signaling and muscle tone. Full-body delivery adds systemic exposure, with secondary vascular, immune and autonomic signaling beyond any single site.

    Local + systemic signaling

  1. 01

    Cellular energy production

    Class IV laser light stimulates cytochrome c oxidase in the mitochondrial membrane, triggering increased ATP synthesis — more fuel for cellular repair, immune response and tissue regeneration.

  2. 02

    Mitochondrial activation

    When light at the right wavelengths reaches mitochondria, electron transport accelerates and energy output rises. Seven clinically selected wavelengths are chosen to reach mitochondrial depth across multiple tissue types.

  3. 03

    Bone and joint support

    Research supports Class IV laser therapy for reducing inflammation around joints. The Pod’s power output lets therapeutic energy reach deeper tissue than lower‑power devices can.

  4. 04

    Nerve and pain modulation

    Class IV laser therapy has demonstrated effects on nerve conduction and pain signaling, reducing local inflammation without pharmaceutical intervention.

Mechanism, not indication

Mechanistic science informs clinical understanding; it does not expand what a device is cleared to do. In U.S. labeling, Summus devices are indicated for the temporary relief of minor muscle and joint pain and stiffness, minor arthritis pain and muscle spasm, a temporary increase in local blood circulation and temporary muscle relaxation.

04Dosimetry

More isnot better.

Light therapy follows a biphasic — hormetic — dose-response. Too little produces no effect, a middle range produces benefit, and excessive dose can blunt or even reverse it (Huang et al., 2009).

That is why dosimetric precision matters: a device that can’t control what it delivers can’t reliably keep every region of the body inside the window. Laser sources offer better inherent dose control, and Pod protocols are designed around the therapeutic range — not at its edges. Following the programmed protocols and session times is how clinicians stay inside it.

The biphasic dose-response

The biphasic dose-response in photobiomodulationBiological response rises with dose to an optimum, the therapeutic window, then blunts and can reverse at excessive dose. Below the curve, a narrow laser dose distribution sits inside the window while a broad LED full-body distribution spills into the too-little and too-much zones. Conceptual illustration after Huang et al., 2009.TOO LITTLEWINDOWTOO MUCHBASELINEOPTIMUMDELIVERED DOSE ACROSS BODYLASERLED FULL-BODYDOSE (LOG SCALE)
Conceptual · after Huang et al., 2009

Irradiance isn’t dose.

A published “50 mW/cm²” describes what reaches a sensor under defined conditions — often at the emitter aperture or 1 cm — not what couples into tissue or reaches mitochondrial photoacceptors. Lambertian LED output falls steeply with distance and angle, so a spec-sheet number is a best case.

Irradiance measured at a probe tip can misrepresent the treatment surface by orders of magnitude (Khan & Arany, 2016), and FDA’s 2023 draft guidance expects manufacturers to characterize wavelength, radiant power, irradiance, fluence, output mode and measurement method — not irradiance alone.

05From targeted therapy to whole‑body optimization

Recovery is nowa systems‑levelconversation.

Traditional Class IV therapy lasers are designed for precision — they focus high power into localized tissue when accuracy matters. The Laser Pod is designed for a different goal: it distributes laser energy uniformly across the body, allowing systemic exposure that supports recovery, circulation and cellular energy processes.

This isn’t about replacing targeted care. It’s about expanding what a modern practice can deliver — consistently, safely and without continuous provider involvement.

  • Uniform light distribution
  • Repeatable dosing, session to session
  • Operator‑independent delivery
  • Designed for preset protocols
Inside the Laser Pod — the open canopy and glass bed lit by rows of Class IV laser emitters
Sources · 8The literature behind this page
  1. 01Huang YY, Chen AC-H, Carroll JD, Hamblin MR. Biphasic dose response in low level light therapy. Dose Response. 2009;7(4):358–383. Source (opens in a new tab)
  2. 02de Freitas LF, Hamblin MR. Proposed mechanisms of photobiomodulation or low-level light therapy. IEEE J Sel Top Quantum Electron. 2016;22(3):348–364. Source (opens in a new tab)
  3. 03Heiskanen V, Hamblin MR. Photobiomodulation: lasers vs light emitting diodes? Photochem Photobiol Sci. 2018;17(8):1003–1017. Source (opens in a new tab)
  4. 04Jacques SL. Optical properties of biological tissues: a review. Phys Med Biol. 2013;58(11):R37–R61. Source (opens in a new tab)
  5. 05Ash C, Dubec M, Donne K, Bashford T. Effect of wavelength and beam width on penetration in light-tissue interaction using computational methods. Lasers Med Sci. 2017;32(8):1909–1918. Source (opens in a new tab)
  6. 06Khan I, Arany PR. Dosimetry for photobiomodulation therapy: response to Sommers et al. Ann Transl Med. 2016;4(10):208. Source (opens in a new tab)
  7. 07Keshri GK, Yadav A, Verma S, Kumar B, Gupta A. Photobiomodulation effects of pulsed-NIR laser (810 nm) and LED (808±3 nm) with identical treatment regimen on burn wound healing: a quantitative label-free global proteomic approach. J Photochem Photobiol. 2021;6:100024. Source (opens in a new tab)
  8. 08U.S. Food and Drug Administration. Photobiomodulation (light therapy) devices — premarket notification [510(k)] submissions. Draft guidance for industry and FDA staff. FDA. 2023. Source (opens in a new tab)

Book a demo

Bring it to your practice.

Book a demo and a representative will walk your team through fit, pricing and what deployment looks like.

Book a demo

Calibrating emitters000%

Summus Medical Laser · Since 2004